Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq slides over 1% as Alphabet results revive AI spending fears
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts ITCI Hot Sheet
Join SI Premium – FREE
Intra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.53), $0.09 better than the analyst estimate of ($0.62).
For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stagwell Inc (STGW) Tops Q3 EPS by 3c ; Offers Guidance
- Alnylam Pharma (ALNY) reported Q3 result ; Offers Guidance
- APi Group Corporation (APG) Tops Q3 EPS by 3c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
The Children's Investment Fund (TCI), EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
